Enterovirus Capsid Interactions with Decay-Accelerating Factor Mediate Lytic Cell Infection
Open Access
- 1 February 2004
- journal article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 78 (3) , 1431-1439
- https://doi.org/10.1128/jvi.78.3.1431-1439.2004
Abstract
The cellular receptor usage of numerous human enteroviruses can differ significantly between low-cell-culture-passaged clinical isolates and highly laboratory-passaged prototype strains. The prototype strain of coxsackievirus A21 (CVA21) displays a dual-receptor specificity as determined with a receptor complex consisting of decay-accelerating factor (DAF) and intercellular adhesion molecule 1 (ICAM-1). In this study, the cellular receptor interactions of low-cell-passage CVA21 clinical isolates with respect to their interactions with cell surface-expressed DAF and ICAM-1 were compared to those of the CVA21 prototype (Kuykendall) strain. Dual-receptor usage of DAF and ICAM-1 by CVA21 clinical isolates was confirmed by cell transfection and radiolabeled binding assays. The cellular attachment of clinical and prototype CVA21 strains to cells that coexpressed DAF and ICAM-1 was not additive compared to the viral binding to cells expressing one or other receptor. In fact, the binding data suggest there is an inhibition of CVA21 cellular attachment in environments where high-level coexpression of both DAF and ICAM-1 occurs. Antibody cross-linking of DAF rendered cells susceptible to lytic infection by the CVA21 clinical isolates. In a novel finding, three clinical isolates could, to various degrees, infect and lyse DAF-expressing cells in the absence of DAF-antibody cross-linking and ICAM-1 expression. Sequence analysis of the P1 region of clinical and prototype virus genomes identified a number of coding changes that may contribute to the observed enhanced DAF usage phenotype of the clinical CVA21 isolates. None of the amino acid changes was located in the previously postulated ICAM-1 footprint, a receptor-binding environment that was conserved on the capsid surface of all CVA21 clinical isolates. Taken together, the data suggest that community-circulating strains of CVA21 can infect target cells expressing either ICAM-1 or DAF alone and that such interactions extend tissue tropism and impact directly on viral pathogenesis.Keywords
This publication has 35 references indexed in Scilit:
- Cellular receptor interactions of C-cluster human group A coxsackievirusesJournal of General Virology, 2003
- Interaction with Decay-Accelerating Factor Facilitates Coxsackievirus B Infection of Polarized Epithelial CellsJournal of Virology, 2002
- Determination of the Structure of a Decay Accelerating Factor-Binding Clinical Isolate of Echovirus 11 Allows Mapping of Mutants with Altered Receptor Requirements for InfectionJournal of Virology, 2002
- GRP78, a Coreceptor for Coxsackievirus A9, Interacts with Major Histocompatibility Complex Class I Molecules Which Mediate Virus InternalizationJournal of Virology, 2002
- Interaction of Coxsackievirus A21 with Its Cellular Receptor, ICAM-1Journal of Virology, 2001
- Clinical Coxsackievirus B Isolates Differ from Laboratory Strains in Their Interaction with Two Cell Surface ReceptorsThe Journal of Infectious Diseases, 1997
- CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choiceNucleic Acids Research, 1994
- Integrins αvβ3 and αvβ5 promote adenovirus internalization but not virus attachmentCell, 1993
- The binding site on ICAM-1 for plasmodium falciparum-infected erythrocytes overlaps, but is distinct from, the LFA-1-binding siteCell, 1992
- Release of decay-accelerating factor (DAF) from the cell membrane by phosphatidylinositol-specific phospholipase C (PIPLC). Selective modification of a complement regulatory protein.The Journal of Experimental Medicine, 1986